Federal Trade Commission is discussing divestiture of Alza's Viadur, a Duros leuprolide product for advanced prostate cancer. TAP, Abbott's joint venture with Takeda, markets leuprolide in a depot formulation as Lupron. The companies say there is "significant interest" in Viadur from other pharmaceutical companies and they still expect to close the merger by the end of the year. Alza submitted an NDA for Viadur around the end of April. FTC is investigating TAP's marketing practices for Lupron
You may also be interested in...
Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011